Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma

2019 ◽  
Author(s):  
Masashi Fujita ◽  
Atsushi Takahashi ◽  
Manabu Hayashi ◽  
Ken Okai ◽  
Kazumichi Abe ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Transarterial Chemoembolization ◽  
Poor Prognosis ◽  
Muscle Volume ◽  
Volume Loss

scholarly journals Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis

Medicine ◽  
2020 ◽  
Vol 99 (28) ◽  
pp. e21061
Author(s):  
Masashi Fujita ◽  
Kazumichi Abe ◽  
Manabu Hayashi ◽  
Atsushi Takahashi ◽  
Hiromasa Ohira
Keyword(s):  
Skeletal Muscle ◽  
Liver Cirrhosis ◽  
Poor Prognosis ◽  
Muscle Volume ◽  
Volume Loss

scholarly journals Hepatocellular carcinoma with disseminated skeletal muscle metastasis

2017 ◽  
Vol 6 (7) ◽  
pp. 205846011771670
Author(s):  
Ezamin Abdul Rahim ◽  
Mohamad SF Noh ◽  
Nur A Ngah ◽  
Mohamad S Suraini ◽  
Mubarak M Yusof
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Poor Prognosis ◽  
Skeletal Muscles ◽  
Rare Case ◽  
Case Reports ◽  
Extrahepatic Metastasis ◽  
Skeletal Muscle Metastasis ◽  
Muscle Metastasis ◽  
To Come

Hepatocellular carcinoma (HCC) is the commonest primary tumor of the liver and carries a poor prognosis when diagnosed late or left untreated. Treatment relies heavily on the stage of the tumor when diagnosed. Extrahepatic metastasis is known to occur; these are mainly reported via autopsy studies or isolated case reports. Knowledge of extrahepatic metastasis is crucial in order to avoid unnecessary surgery. We report a rare case of a patient at our center, diagnosed to have HCC, who underwent treatment successfully, only to come back with extrahepatic metastasis to the skeletal muscles.

Postoperative pneumonia causes the loss of skeletal muscle volume and poor prognosis in patients undergoing esophagectomy for esophageal cancer

2020 ◽  
Vol 69 (1) ◽  
pp. 84-90
Author(s):  
Seiichiro Fujishima ◽  
Hironori Tsujimoto ◽  
Ken Nagata ◽  
Hidekazu Sugasawa ◽  
Shinsuke Nomura ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Esophageal Cancer ◽  
Poor Prognosis ◽  
Muscle Volume ◽  
Postoperative Pneumonia

Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease

2018 ◽  
Vol 33 (9) ◽  
pp. 1659-1666 ◽  
Author(s):  
Yoshihiko Tachi ◽  
Akihiro Kozuka ◽  
Takanori Hirai ◽  
Yoji Ishizu ◽  
Takashi Honda ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Muscle Volume ◽  
Chronic Liver ◽  
Volume Loss

scholarly journals Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2247
Author(s):  
Issei Saeki ◽  
Takahiro Yamasaki ◽  
Yurika Yamauchi ◽  
Taro Takami ◽  
Tomokazu Kawaoka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Independent Predictor ◽  
Progression Free Survival ◽  
Muscle Volume ◽  
Clinical Parameters ◽  
Sorafenib Treatment ◽  
Skeletal Muscle Index ◽  
Free Survival ◽  
The Relationship

Few studies exist on the relationship between post-progression survival (PPS) and skeletal muscle volume in hepatocellular carcinoma (HCC) patients receiving sorafenib. This study aimed to analyze the effects of muscle volume on clinical outcomes. We retrospectively enrolled 356 HCC patients. Various clinical parameters, including skeletal muscle index, were analyzed as predictors of overall survival (OS), progression-free survival (PFS), and PPS. Patients with high muscle volume showed longer survival or PPS than those with low muscle volume (median survival time: 12.8 vs. 9.5 months, p = 0.005; median PPS: 8.2 vs. 6.3 months, p = 0.015); however, no differences in PFS were found. Multivariate analysis indicated that muscle volume was an independent predictor of PPS and OS. Skeletal muscle volume was a PPS predictor in HCC patients receiving sorafenib. Therefore, survival can be prolonged by the upregulation of skeletal muscle volume, especially in HCC patients with skeletal muscle depletion.

scholarly journals Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Takamasa Kobayashi ◽  
Hirokazu Kawai ◽  
Oki Nakano ◽  
Satoshi Abe ◽  
Hiroteru Kamimura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Poor Prognosis ◽  
Skeletal Muscle Mass

scholarly journals Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis

2018 ◽  
Vol 10 (10) ◽  
pp. 765-771 ◽  
Author(s):  
Kazuhiro Katayama ◽  
Toshihiro Imai ◽  
Yutaro Abe ◽  
Tadatoshi Nawa ◽  
Noboru Maeda ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Poor Prognosis
Sign in / Sign up

Export Citation Format

Share Document